Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Neratinib (HKI-272)

1 Open Trial

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCMD1403

    06/02/2014

    An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification


    Print this page for your doctor